Skip to Content

Cancidas (caspofungin) Disease Interactions

There are 2 disease interactions with Cancidas (caspofungin):

Moderate

Caspofungin (Includes Cancidas) ↔ liver disease

Moderate Potential Hazard, High plausibility. Applies to: Liver Disease

Caspofungin is primarily metabolized by the liver. In a single-dose study, plasma concentrations of caspofungin after a 70 mg dose in patients with mild hepatic impairment (Child-Pugh score 5 to 6) increased by approximately 55% compared to healthy control subjects, whereas patients with moderate hepatic impairment (Child-Pugh score 7 to 9) had an average plasma increase of 76%. In a 14-day multiple-dose study (70 mg on the first day followed by 50 mg daily), plasma concentrations in patients with mild hepatic impairment were increased modestly by about 19% to 25% on days 7 and 14 relative to healthy control subjects. No dosage adjustment is necessary in patients with mild hepatic impairment. For patients with moderate hepatic impairment, a reduced dosage of 35 mg/day is recommended following the initial 70 mg loading dose. There is no clinical experience with caspofungin in patients with severe hepatic impairment.

References

  1. "Product Information. Cancidas (caspofungin)" Merck & Co, Inc, West Point, PA.
Moderate

Echinocandins (Includes Cancidas) ↔ hepatotoxicity

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Laboratory abnormalities in liver function tests have been observed in healthy volunteers and patients treated with echinocandins, and clinical hepatic abnormalities have occurred in some patients with serious underlying conditions who were receiving multiple concomitant medications with echinocandin therapy. Isolated cases of significant hepatic dysfunction, hepatitis, or worsening hepatic failure have also been reported, although a causal relationship has not been established. Therapy with echinocandins should be administered cautiously in patients with preexisting liver disease. Liver function should be monitored regularly during therapy.

References

  1. "Product Information. Mycamine (micafungin)." Fujisawa, Deerfield, IL.
  2. "Product Information. Eraxis (anidulafungin)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
  3. "Product Information. Cancidas (caspofungin)" Merck & Co, Inc, West Point, PA.

Cancidas (caspofungin) drug interactions

There are 55 drug interactions with Cancidas (caspofungin)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide